Innovative Irinotecan-Loaded Nanomicelles Will Enter Phase I Clinical Trial in 2021

Recent progress at the National Center for Nanoscience and Technology of China has enabled an extremely facile method to encapsulate irinotecan (CPT-11) into micelle-based nanoparticles (named as IH-NM). In preclinical study, compared with free CPT-11, IH-NM exhibited 1.56-fold higher maximum tolera...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Chan, Xu, Jing, Gan, Yaling, Liang, Xing-Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Translational Patent
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8454605/
https://www.ncbi.nlm.nih.gov/pubmed/34557721
http://dx.doi.org/10.1016/j.xinn.2020.100057
_version_ 1784570524161015808
author Li, Chan
Xu, Jing
Gan, Yaling
Liang, Xing-Jie
author_facet Li, Chan
Xu, Jing
Gan, Yaling
Liang, Xing-Jie
author_sort Li, Chan
collection PubMed
description Recent progress at the National Center for Nanoscience and Technology of China has enabled an extremely facile method to encapsulate irinotecan (CPT-11) into micelle-based nanoparticles (named as IH-NM). In preclinical study, compared with free CPT-11, IH-NM exhibited 1.56-fold higher maximum tolerance dose (MTD), ∼2.45-fold higher antitumor efficacy at 80% of MTD dosage, higher plasma exposure, and slower clearance from the plasma. The IH-NM technology received Clinical Trial Permission from the National Medical Products Administration (NMPA) of China on Mar 6, 2019. The Phase I clinical trial is under preparation.
format Online
Article
Text
id pubmed-8454605
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-84546052021-09-22 Innovative Irinotecan-Loaded Nanomicelles Will Enter Phase I Clinical Trial in 2021 Li, Chan Xu, Jing Gan, Yaling Liang, Xing-Jie Innovation (Camb) Translational Patent Recent progress at the National Center for Nanoscience and Technology of China has enabled an extremely facile method to encapsulate irinotecan (CPT-11) into micelle-based nanoparticles (named as IH-NM). In preclinical study, compared with free CPT-11, IH-NM exhibited 1.56-fold higher maximum tolerance dose (MTD), ∼2.45-fold higher antitumor efficacy at 80% of MTD dosage, higher plasma exposure, and slower clearance from the plasma. The IH-NM technology received Clinical Trial Permission from the National Medical Products Administration (NMPA) of China on Mar 6, 2019. The Phase I clinical trial is under preparation. Elsevier 2020-11-04 /pmc/articles/PMC8454605/ /pubmed/34557721 http://dx.doi.org/10.1016/j.xinn.2020.100057 Text en © 2020 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Translational Patent
Li, Chan
Xu, Jing
Gan, Yaling
Liang, Xing-Jie
Innovative Irinotecan-Loaded Nanomicelles Will Enter Phase I Clinical Trial in 2021
title Innovative Irinotecan-Loaded Nanomicelles Will Enter Phase I Clinical Trial in 2021
title_full Innovative Irinotecan-Loaded Nanomicelles Will Enter Phase I Clinical Trial in 2021
title_fullStr Innovative Irinotecan-Loaded Nanomicelles Will Enter Phase I Clinical Trial in 2021
title_full_unstemmed Innovative Irinotecan-Loaded Nanomicelles Will Enter Phase I Clinical Trial in 2021
title_short Innovative Irinotecan-Loaded Nanomicelles Will Enter Phase I Clinical Trial in 2021
title_sort innovative irinotecan-loaded nanomicelles will enter phase i clinical trial in 2021
topic Translational Patent
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8454605/
https://www.ncbi.nlm.nih.gov/pubmed/34557721
http://dx.doi.org/10.1016/j.xinn.2020.100057
work_keys_str_mv AT lichan innovativeirinotecanloadednanomicelleswillenterphaseiclinicaltrialin2021
AT xujing innovativeirinotecanloadednanomicelleswillenterphaseiclinicaltrialin2021
AT ganyaling innovativeirinotecanloadednanomicelleswillenterphaseiclinicaltrialin2021
AT liangxingjie innovativeirinotecanloadednanomicelleswillenterphaseiclinicaltrialin2021

Ejemplares similares